Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Transdermal cannabinoids may provide better safety and bioavailability profiles compared with other routes of administration. This single-arm, open-label study investigated a novel topical transdermal delivery system on the pharmacokinetics of cannabidiol (CBD) and tetrahydrocannabinol (THC).
Methods: Participants were 39.5 ± 7.37 years old and healthy, based on a review by the Medical Director. Blood was collected pre-dose and 10, 20, 30, and 45 min, and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 h after topical application of 100 mg CBD:100 mg THC. Psychoactive effects were assessed prior to each timepoint. Area-under-the-curve (AUC), maximum concentration (C), time to maximum concentration (T), area-under-the-curve to infinity (AUC), terminal elimination rate constant (λ), terminal half-life (t½), and absorption rate constant (k) were measured individually for CBD and THC. Safety was assessed by clinical chemistry, hematology, and adverse events.
Results: AUC for CBD and THC was 3329.8 ± 3252.1 and 2093.4 ± 2090.6 pg/mL/h, with C of 576.52 ± 1016.18 and 346.57 ± 776.85 pg/mL, respectively. T for CBD and THC was 8 h, ranging from 2.5 h to 12 h and 10 min to 12 h, respectively. AUC for CBD and THC was 6609.2 ± 7056.4 and 3721.0 ± 3251.7 pg/mL/h, with t of 5.68 ± 1.5 and 5.38 ± 1.25 h, respectively. CBD was absorbed at a faster rate compared with THC (123.36 ± 530.97 versus 71.5 ± 1142.19 h) but with similar λ (0.12 ± 0.029 versus 0.13 ± 0.03 h). No psychoactive effects were reported. Transdermal cannabinoid delivery was safe and well tolerated in the population studied.
Conclusion: To our knowledge, this is the first pharmacokinetic study in humans that demonstrated CBD and THC entering systemic circulation via transdermal administration . This study represents an important contribution to understanding the pharmacokinetics of transdermal cannabinoids.
Clinical Trial Registration: ClinicalTrials.gov Identifier-NCT05121506 (November 16, 2021).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859876 | PMC |
| http://dx.doi.org/10.1007/s12325-022-02345-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
UGT2B7-mediated drug-drug interaction between cannabinoids and hydromorphone.
Drug Metab Dispos
July 2025
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York
Hydromorphone is a highly potent opioid used to treat severe chronic pain. It is metabolized primarily by UDP-glucuronosyltransferase (UGT)2B7 to form the inactive hydromorphone-3-glucuronide. Given that previous studies have shown that the major cannabinoids, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), inhibit several UGT enzymes, the objective of the present study was to determine the inhibitory potential of major cannabinoids and their metabolites on UGT-mediated hydromorphone metabolism.
View Article and Find Full Text PDFDaily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.
Med Sci Sports Exerc
September 2025
Research Institute of Sport and Exercise Sciences (RISES), Liverpool John Moores University, Byrom Street, Liverpool, UNITED KINGDOM.
Background: Cannabidiol (CBD), a non-intoxicating phytocannabinoid, is used by athletes to enhance recovery and manage other conditions (e.g., poor sleep, anxiety).
View Article and Find Full Text PDFAnalgesic and toxicological evaluation of cannabidiol-rich Moroccan L. (Khardala variety) extract: Evidence from an and study.
Open Life Sci
September 2025
Physiology and Physiopathology Team, Faculty of Sciences, Genomic of Human Pathologies Research Centre, Mohammed V University in Rabat, Rabat, Morocco.
The legalization of cannabis for industrial and medicinal purposes has significantly expanded worldwide. This study delves into the analgesic potential toxicity study of chloroformic extract from the Moroccan L. () cultivar, Khardala (KH extract).
View Article and Find Full Text PDFEffects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination.
Hum Psychopharmacol
September 2025
Psychology and Neuroscience, University of Colorado Boulder, Boulder, Colorado, USA.
Objective: This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research.
Methods: Participants were either not using cannabis, using cannabis with THC, or using cannabis with CBD and were assessed at baseline, 2 weeks, and 4-weeks following ad libitum use of a legal market cannabis product that was randomly assigned to them. Primary outcomes included scores on the Depression Anxiety Stress (DASS) Scale and number of drinking days.
Cannabis Use Characteristics and Reasons for Product Choices Among Patients Accessing Treatment for Substance Use Disorders: A Mixed-Methods Study.
Cannabis
July 2025
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health.
Objective: The diversity and potency of cannabis products have increased in recent years, underscoring the importance of understanding which products are being used and why. Patients with substance use disorders (SUDs) use have a high prevalence of risky cannabis use, making it especially important to understand use patterns in this group. We aimed to first describe cannabis product characteristics and then explore reasons for choosing products in our sample.
View Article and Find Full Text PDF